What Does it Cover?
The complexity of target identification requires robust, innovative methodologies to improve the efficiency and success rates for developing new therapeutics. However, traditional methods of drug discovery are often time-consuming, costly, and inefficient. In this webinar, learn how to overcome these hurdles by leveraging the power of DNA Encoded Libraries (DEL) and Micromapping technologies. The mapping platform enables precise identification of protein-protein interactions on cell membranes. Utilizing a photocatalyst-antibody conjugate, this breakthrough technology allows selective labeling of antibody-binding targets and their microenvironment protein neighbors. The DNA-encoded library (DEL) technology enables the screening of millions of small molecules and fragment-based compounds that specifically bind to protein targets in a single experiment. The unparalleled diversity of chemical compounds greatly expands the chemical space that can be explored, increasing the chances of identifying novel and potent potential drug candidates.
What Will You Learn?
- Impact of DNA Encoded Libraries (DEL) on drug discovery.
- Selective labeling of antibody binding targets on cell membranes.
- Micromapping technology for precise protein interaction identification.
Speaker
Hugo Matos Viana
Merck
Global Product Manager - Chemical Biology
Hugo Matos Viana is a life science professional with extensive technical and business expertise in Chemistry. In his current role, he is responsible for overseeing the Chemical Biology portfolio strategy at Merck KGaA, Darmstadt, Germany. Hugo holds a PhD in Organic Chemistry and is attending an Executive MBA program.
Lead discovery
- Pharmacology and drug discovery research
Durée:1h
Langue:English
Session 1:présenté(e) March 26, 2024
Session 2:présenté(e) April 11, 2024
Pour continuer à lire, veuillez vous connecter à votre compte ou en créer un.
Vous n'avez pas de compte ?